Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9135758 | PMC |
| http://dx.doi.org/10.1038/s41392-022-00982-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deconstructing the intra-tumor subclonal heterogeneity of lung synchronous ground-glass nodules using whole-genome sequencing.
Signal Transduct Target Ther
May 2022
State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, China.
Tumor deconstruction as a tool for advanced drug screening and repositioning.
Pharmacol Res
September 2016
National Centre for Cell Science, NCCS Complex, Pune 411007, India. Electronic address:
A major focus of contemporary drug screening strategies is the identification of novel anticancer compounds, which often results in underutilization of resources. Current drug evaluation involves in vivo tumor (xenograft) regression as proof-of-principle for cytotoxicity (POC). However, this end-point lacks any assessment of drug resistance of the residual tumor and its capability to establish refractory and/or recurrent disease, which would represent more appropriate indicators of therapeutic failure.
View Article and Find Full Text PDFThe second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
Oncotarget
February 2016
INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Institut Curie, Paris, France.
Despite multimodal treatment, long term outcome for patients with Ewing sarcoma is still poor. The second "European interdisciplinary Ewing sarcoma research summit" assembled a large group of scientific experts in the field to discuss their latest unpublished findings on the way to the identification of novel therapeutic targets and strategies. Ewing sarcoma is characterized by a quiet genome with presence of an EWSR1-ETS gene rearrangement as the only and defining genetic aberration.
View Article and Find Full Text PDFA tumor deconstruction platform identifies definitive end points in the evaluation of drug responses.
Oncogene
February 2016
National Centre for Cell Science, NCCS Complex, Pune, India.
Tumor heterogeneity and the presence of drug-sensitive and refractory populations within the same tumor are almost never assessed in the drug discovery pipeline. Such incomplete assessment of drugs arising from spatial and temporal tumor cell heterogeneity reflects on their failure in the clinic and considerable wasted costs in the drug discovery pipeline. Here we report the derivation of a flow cytometry-based tumor deconstruction platform for resolution of at least 18 discrete tumor cell fractions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!